edoxaban and aspirin

Additive pharmacodynamic interaction: edoxaban inhibits factor Xa, reducing thrombin generation and clot formation, while aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), suppressing thromboxane A2-mediated platelet aggregation. Combined use produces overlapping impairment of haemostasis, significantly increasing bleeding risk.

The combination of edoxaban and aspirin increases the risk of major bleeding, including gastrointestinal bleeding and intracranial haemorrhage, compared with either agent alone. This is particularly concerning in patients with additional risk factors such as advanced age, renal impairment, or prior bleeding events.

Avoid concomitant use unless the benefit of antiplatelet therapy outweighs the bleeding risk (e.g., acute coronary syndrome or coronary stenting). If combined treatment is necessary, use the lowest effective aspirin dose, limit the duration of dual therapy, and monitor closely for signs of bleeding (e.g., haemoglobin, stools). Review the need for aspirin regularly and consider gastroprotection with a proton pump inhibitor.

Well established from clinical trials of direct oral anticoagulants combined with antiplatelet agents, which show dose-dependent increases in bleeding. The risk is supported by pharmacodynamic studies and post-marketing surveillance. Guidance from major cardiology societies recommends caution and limited duration when combining anticoagulant and antiplatelet therapy.